Wednesday, February 24, 2021 Daily Archives

Process intensification and PAT essential for achieving real-time release

Development of complex methods enabling real-time release of therapeutics requires creativity and collaboration, say experts from NIIMBL and SCIEX. Interest in real-time release (RTR) is driving the industry to think about process intensification in a coordinated manner. Process intensification offers the potential for increased efficiencies and thereby reduced cost and time for drug production. Workflows, capital and operating expenses, product quality, and waste production can all be positively impacted. There is consequently a push in the industry to develop and…

Catalent commits to pDNA, buying Delphi and expanding a Maryland plant

Having its own plasmid DNA capabilities will launch Catalent into areas like mRNA and non-viral gene delivery, the CDMO says. Catalent has entered into an agreement to buy fellow contract development and manufacturing organization (CDMO) Delphi Genetics, adding – if the deal goes through – a plasmid DNA (pDNA) platform and supporting production services from preclinical to Phase III. The deal, financial details of which have not been divulged, will also bring Catalent a 17,000 square-foot facility in Gosselies, Belgium,…